Z-360, a Novel Cholecystokinin-2/Gastrin Receptor Antagonist, Inhibits Gemcitabine-Induced Expression of the Vascular Endothelial Growth Factor Gene in Human Pancreatic Cancer Cells
スポンサーリンク
概要
- 論文の詳細を見る
Z-360 is a novel cholecystokinin (CCK)-2/gastrin receptor antagonist that is being developed for the treatment of pancreatic adenocarcinoma in combination with gemcitabine. A previous study shows that the co-administration of Z-360 with gemcitabine significantly prolonged the survival of mice with orthotopically implanted human pancreatic adenocarcinoma cell lines. To clarify the therapeutic effects of Z-360 in combined with gemcitabine, we analyzed gene expression. When gemcitabine was administered, CCK-2/gastrin receptor expression was induced in an orthotropic xenograft model; the result indicating that Z-360 could act on gemcitabine-sensitive cells. Both in vitro and in vivo studies showed that gemcitabine increased the expression of vascular endothelial growth factor A (VEGFA), a prognostic factor for survival in pancreatic cancer, while Z-360 suppressed this induction of VEGFA gene expression. These results help to explain how Z-360 prolongs survival when used in combination with gemcitabine.
著者
-
Yoshinaga Koji
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd.
-
Hamano Hiroki
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd.
-
Orikawa Yuki
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd.
-
Seto Koichi
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd.
-
Takei Mineo
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd.
-
Takei Mineo
Central Research Laboratories Zeria Pharmaceutical Co. Ltd.
-
Hamano Hiroki
Central Res. Laboratories Zeria Pharmaceutical Co. Ltd.
-
Yoshinaga Koji
Central Res. Laboratories Zeria Pharmaceutical Co. Ltd.
-
Kobayashi Nobuyoshi
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd.
関連論文
- Pharmacological Evaluation of Analgesic Effects of the Cholecystokinin2 Receptor Antagonist Z-360 in Mouse Models of Formalin- and Cancer-Induced Pain
- Z-100, an Immunomodulatory Arabinomannan Extracted from Mycobacterium tuberculosis Strain Aoyama B, Augments Anti-tumor Activities of X-Ray Irradiation against B16 Melanoma in Association with the Improvement of Type 1T Cell Responses(Miscellaneous)
- Antimetastatic Effect of an Immunomodulatory Arabinomannan Extracted from Mycobacterium tuberculosis Strain Aoyama B, Z-100, through the Production of Interleukin-12(Miscellaneous)
- Anti-Tumor Mechanism of Z-100, an Immunomodulatory Arabinomannan Extracted from Mycobacterium tuberculosis Strain Aoyama B, on Pulmonary Metastases of B16F10 Melanoma : Restoration of Helper T Cell Responses via Suppression of Glucocorticoid-Genesis
- Z-360, a Novel Cholecystokinin-2/Gastrin Receptor Antagonist, Inhibits Gemcitabine-Induced Expression of the Vascular Endothelial Growth Factor Gene in Human Pancreatic Cancer Cells
- CHANGES IN TISSUE CONTENTS OF ZINC, COPPER AND IRON IN RATS AND BEAGLE DOGS TREATED WITH POLAPREZINC
- 101 CHANGES IN CONTENTS OF ZINC, COPPER AND IRON IN ANIMAL TISSUES AFTER REPEATED ORAL ADMINISTRATION OF Z-103
- Hormonal Effects of Z-350, Possessing Steroid 5α-Reductase Inhibitory and α_1-Adrenoceptor Antagonistic Actions, in the Rat
- Z-335,a Thromboxane A_2 Receptor Antagonist, Suppresses the Progression of Arachidonic Acid-Induced Hind Limb Gangrene in Rats
- Arachidonic Acid-Induced Hind Limb gangrene : A New Experimental Rat Model of Paripheral Vascular Disease
- Fasting Exacerbates Acute Pancreatitis by Occlusion of the Common Bile Duct in Rats
- Diet Stimulation as a Synergistic Factor of Aggravation in a Pancreatic Bile Duct Ligation-Induced Rat Pancreatitis Model
- Cholecystokinin Acts as an Essential Factor in the Exacerbation of Pancreatic Bile Duct Ligation-Induced Rat Pancreatitis Model Under Non-fasting Condition